BidSonarBidSonar
ContractsGrantsOrganisationsSectors
BidSonarBidSonar·Built by Hypership
SourcesPrivacyTermsCookies

BidSonar is an independent index of public-sector opportunities. We aggregate data from official sources and are not affiliated with any procurement body. Data is licensed under the Open Government Licence v3.0 and the EU TED reuse notice.

    ContractsNon-Exclusive Discount Agreements for Pharmaceuticals
    Open tender

    Non-Exclusive Discount Agreements for Pharmaceuticals

    Tender closes
    132d
    31 Dec 2026 · in 19 weeks

    The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process will provide uniform contract conditions and access procedu

    🇩🇪GermanyPublished 26 Aug 2025· 12 months agoviaTED
    Tender closes
    132d
    31 Dec 2026 · in 19 weeks

    Decision brief

    4 fields
    • Contract value
      Not disclosed
      Source did not declare a figure
    • Tender closes
      31 Dec 2026
      132 days left
    • Sector
      Healthcare & Medical
      Browse related listings
    • Location
      🇩🇪Germany

    Lifecycle

    Open

    132 days left to bid. Opened 12 months ago, deadline 31 Dec 2026.

    26 Aug 2025Today31 Dec 2026

    Brief

    The KKH (Kaufmännische Krankenkasse) aims to establish non-exclusive discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process will provide uniform contract conditions and access procedures, allowing all eligible and interested pharmaceutical companies or consortia to enter into or join a discount agreement for the active ingredients mentioned in the tender. Interested pharmaceutical companies can request participation documents and the contract at the provided contact address (rabattvertraege@kkh.de). The deadline for participation is December 31, 2026.

    More from KKH COMMERCIAL HEALTH INSURANCE

    4 listingsView all →
    Healthcare & Medical🇩🇪Germany

    Non-Exclusive Discount Agreements for Pharmaceuticals

    The KKH (Kaufmännische Krankenkasse) is seeking to establish non-exclusive discount agreements with pharmaceutical companies for specific active ingredients under the Open-House procedure. This opportunity is open to all qualified pharmaceutical companies interested in entering into discount agreeme

    KKH COMMERCIAL HEALTH INSURANCE
    Published 26 Feb 2026
    Healthcare & Medical🇩🇪Germany

    Germany – Pharmaceutical Discounts Agreement

    The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under Section 130a (8) of the Social Code Book V (SGB V) through an 'Open-House' procedure. This process allows all eligible and interested pharm

    KKH COMMERCIAL HEALTH INSURANCE
    Published 22 Feb 2026
    Healthcare & Medical🇩🇪Germany

    Germany – Pharmaceutical Discounts Agreement

    The KKH (Kaufmännische Krankenkasse) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies or groups to

    KKH COMMERCIAL HEALTH INSURANCE
    Published 17 Dec 2025
    Healthcare & Medical🇩🇪Germany

    Germany – Pharmaceutical Discounts Agreement

    The Kaufmännische Krankenkasse (KKH) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a paragraph 8 of the Social Code Book V. This process will provide uniform contract conditions and acc

    KKH COMMERCIAL HEALTH INSURANCE
    Published 30 Nov 2025

    Open in Healthcare & Medical

    4 open listingsView all →
    Healthcare & Medical🇬🇧United Kingdom

    Early Cancer Diagnostic Technologies Development Programme

    Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.

    est.£25,400,000
    Published 1 Sept 2026
    Healthcare & Medical🇬🇧United Kingdom

    Clinical Validation of Early Cancer Diagnostic Technologies

    Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.

    est.£25,400,000
    Published 1 Sept 2026
    OpenHealthcare & Medical🇬🇧United Kingdom

    Doxycycline 10-Pack Supply - Market Engagement 2027

    UKHSA seeks supplier information for Doxycycline 10-pack supply through a preliminary market engagement exercise under the Procurement Act 2023.

    £1nominalSecretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
    Published 21 Aug 2026
    OpenHealthcare & Medical🇬🇧United Kingdom

    Patient Diagnostic and Monitoring Electrodes - Market Engagement Survey

    Suppliers are invited to complete a preliminary market engagement questionnaire about patient diagnostic and monitoring electrodes by 21st September 2026 through eTendersNI.

    Business Services Organisation Procurement and Logistics
    Published 21 Aug 2026
    Take action
    View tender on sourceTED

    Full notice and submission process on the publisher's site

    Publisher
    Publications Office of the European Union
    Licence
    EU 2011/833/EU + TED reuse notice
    Source
    ted.europa.eu
    Record ID
    557405-2025
    KC
    Buyer
    KKH COMMERCIAL HEALTH INSURANCE
    Sector
    Healthcare & Medical